This application aims to facilitate research on eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), and eosinophilic colitis (EC) through the development of a Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). CEGIR comprises clinical centers in Ohio (the coordinating center), Colorado, California, Indiana, Pennsylvania, Illinois, North Carolina, Massachusetts, Switzerland, and Maryland. All participating domestic, non-National Institutes of Health (NIH) clinical centers are associated with a Clinical Translational Science Award (CTSA). The CEGIR sites have been carefully chosen on the basis of their preexisting record of collaboration with each other;diverse expertise in relevant clinical specialties including Gastroenterology, Allergy, Immunology, and Pathology;the ability to integrate pediatric and adult patients into a common consortium;and well-established record of excellence in clinical research involving this patient population. Importantly, the CEGIR sites have proven access to an adequate number of patients with the rare diseases studied, as evidenced from the recent completion of the first set of controlled clinical trials involving this patient population. Strong patient advocacy groups (PAGs), including the American Partnership for Eosinophilic Disorders (APFED) and the Campaign Urging Research for Eosinophilic Disease (CURED), already partner with the CEGIR Investigators and will continue to work synergistically in the context of CEGIR. Despite the recent record of advances by CEGIR Investigators, the early success of their collaborative interactions, the proactive PAGs, and the development of novel anti-eosinophil therapeutics, there is no currently existing funding for a clinical network focusing on these three rare, distinct diseases, highlightig the timeliness and importance of this application.
Eosinophilic esophagitis, eosinophilic gastritis, and eosinophilic colitis are painful, lifelong diseases that make it difficult or impossible for indiviuals to eat many or all foods. Individuals with these diseases often have to fuel their bodies by drinking costly formulas. We will partner with researchers, patients, and other key groups, including patient advocacy groups, to better understand, treat, and educate about these diseases.
|Mehta, Pooja; Sundaram, Shikha; Furuta, Glenn T et al. (2016) Propofol Use in Pediatric Patients With Food Allergy and Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr :|
|Molina-Infante, Javier; Bredenoord, Albert J; Cheng, Edaire et al. (2016) Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut 65:524-31|
|Imam, Tanbeena; Gupta, Sandeep K (2016) Topical glucocorticoid vs. diet therapy in eosinophilic esophagitis: the need for better treatment options. Expert Rev Clin Immunol 12:797-9|
|Kliewer, Kara L; Venter, Carina; Cassin, Alison M et al. (2016) Should wheat, barley, rye, and/or gluten be avoided in a 6-food elimination diet? J Allergy Clin Immunol 137:1011-4|
|Morris, David W; Stucke, Emily M; Martin, Lisa J et al. (2016) Eosinophil progenitor levels are increased in patients with active pediatric eosinophilic esophagitis. J Allergy Clin Immunol 138:915-918.e5|
|Watts, Abhishek; Alexander, Jeffrey A; Gupta, Sandeep K (2016) Eosinophilic esophagitis: search for noninvasive techniques for long-term monitoring. Gastrointest Endosc 83:307-8|
|Hill, David A; Spergel, Jonathan M (2016) The Immunologic Mechanisms of Eosinophilic Esophagitis. Curr Allergy Asthma Rep 16:9|
|Gonsalves, Nirmala; Furuta, Glenn T; Atkins, Dan (2016) Eosinophilic Gastrointestinal Disorders Affect More Than Just the Esophagus. J Pediatr Gastroenterol Nutr 62:1-2|
|Nguyen, Nathalie; Furuta, Glenn T; Masterson, Joanne C (2016) Deeper Than the Epithelium: Role of Matrix and Fibroblasts in Pediatric and Adult Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr 63:168-9|
|Rawson, Renee; Yang, Tom; Newbury, Robert O et al. (2016) TGF-Î²1-induced PAI-1 contributes to a profibrotic network in patients with eosinophilic esophagitis. J Allergy Clin Immunol 138:791-800.e4|
Showing the most recent 10 out of 37 publications